Ischemic Injury Articles & Analysis
7 news found
Carleton Hsia, NanoBlood: NanoBlood LLC has developed VitalHemeTM (nanoRBC), an innovative multifunctional neurovascular protective agent for the prevention and treatment of ischemia, reperfusion injury and damaging inflammatory reactions caused by superoxide generation. ...
The disease that Villix first targeted is ischemic reperfusion injury that occurs in organ transplant myocardial infarction, coronary artery bypass surgery, and stroke. ...
In pre-clinical data, TSC has been observed to affect oxygen diffusion to hypoxic tissues and provide a functional benefit in animal models of GBM, acute respiratory distress syndrome/acute lung injury, hemorrhagic shock, and ischemic stroke. About Diffusion Pharmaceuticals Inc. ...
ByCervoMed
Interest in bilirubin is high worldwide. This is because bilirubin has already received attention as a substance that has strong antioxidant effects and immunomodulatory effects through 30,000 papers from several decades ago. However, there were clear limitations in developing it as a new drug. This is because it is extremely hydrophobic, insoluble in water. It is Bilix that solved this problem. ...
Currently, the primary challenge ahead is the development of treatments for ischemic reperfusion injury (IRI). To date, there are no drugs approved for the treatment of IRI. ...
The disease that Bilix has targeted is ischemic reperfusion injury caused by organ transplantation, myocardial infarction, coronary artery bypass grafting, and stroke. ...
” Because the drug Simvastatin has been demonstrated to be a neurorestorative and neuroprotective agent in ischemic brain injury, the research team hypothesized that the combination of therapeutic doses of Simvastatin and HUCBCs would increase the expression of Angiopoietin-1(Ang-1, a protein with important roles in vascular development and blood vessel ...